Shots:

• The approval is based on two P-III studies that evaluate Twyneo vs vehicle in adults & pediatric patients aged ≥9yrs. with acne vulgaris which demonstrated an efficacy & a favorable tolerability profile
• Twyneo utilizes Sol-Gel’s microencapsulation technology to entraps tretinoin & benzoyl peroxide within silica-based microcapsules. Additionally- the company collaborated with Galderma to commercialize Twyneo in the US
• Sol-Gel to receive a regulatory milestone in conjunction with FDA's approval & retains the option to regain US commercialization rights for five yrs. after the 1st commercialization in the US. Twyneo is patent protected until 2038

| Ref: Sol-Gel | Image: Twitter